James SULAT

About James SULAT

James Sulat is a highly experienced life sciences and biotechnology governance professional with a long career spanning senior leadership and board roles. At Valneva SE, he serves as a member of the Board of Directors and chairs the Audit Committee, a pivotal role that involves oversight of financial reporting, internal controls, risk management, and compliance. His position on the board reflects deep expertise in finance, corporate governance, and oversight of international growth companies. Before joining Valneva’s board, Sulat built a strong reputation in the biopharmaceutical sector through senior executive responsibilities. Valneva identifies him as a former Chief Financial Officer of Chiron and former Chief Executive Officer of Maxygen. Additional corporate and governance sources linked to his prior mandates show that he has spent many years advising and leading life sciences companies, particularly through periods of development, financial structuring, and shareholder value creation. His background is especially relevant for a vaccine company such as Valneva. With experience both as an executive and as a board member, he brings a disciplined perspective on capital allocation, financing needs, industrial risk, and the regulatory complexity of vaccine development and commercialization. As Audit Committee chair, he helps strengthen financial discipline and the credibility of control processes, both of which are essential for a listed company operating in a demanding environment. Sulat has also been associated with Valneva’s governance evolution, as the company transitioned from a two-tier structure to a more standard one-tier board model. In that context, his presence signals continuity in strategic oversight and a strong focus on governance quality. For investors and sector observers, he stands out as an accomplished independent director combining financial expertise, deep biotech experience, and a strong understanding of the responsibilities of listed-company oversight.